Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic and biochemical evidence.
Very little is known about the applicability of the metabolic and biochemical events observed in cell culture systems to in vivo tumor shrinkage following photodynamic therapy (PDT). The purpose of this study was to assess whether PDT induces apoptosis during tumor ablation in vivo. We treated radiation-induced fibrosarcoma (RIF-1) tumors grown in C3H/HeN mice with PDT employing three photosensitizers, Photofrin-II, chloroaluminum phthalocyanine tetrasulfonate, or Pc IV (a promising phthalocyanine developed in this laboratory). Each photosensitizer was injected intraperitoneally and 24 h later the tumors were irradiated with an appropriate wavelength of red light using an argon-pumped dye laser. During the course of tumor shrinkage, the tumors were removed at 1, 2, 4 and 10 h post-PDT for DNA fragmentation, histopathologic, and electron microscopic studies. Markers of apoptosis, viz. the ladder of nucleosome-size DNA fragments, increased apoptotic bodies, and condensation of chromatin material around the periphery of the nucleus, were evident in tumor tissue even 1 h post-PDT; the extent of these changes increased during the later stages of tumor ablation. No changes were observed in tumors given photosensitizer alone or irradiation alone. Our data suggest that the damage produced by in vivo PDT may activate endonucleolysis and chromatin condensation, and that apoptosis is an early event in tumor shrinkage following PDT.
Zaidi
S I
SI
Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, OH 44106.
Oleinick
N L
NL
Zaim
M T
MT
Mukhtar
H
H
D000818:Animals; D017209:Apoptosis; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000378:metabolism; D017323:Dihematoporphyrin Ether / Q000627:therapeutic use; D005354:Fibrosarcoma / Q000473:pathology / Q000532:radiotherapy*; D007211:Indoles / Q000627:therapeutic use; D051379:Mice; D008809:Mice, Inbred C3H; D009942:Organometallic Compounds / Q000627:therapeutic use; D017646:Organosilicon Compounds / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012821:Silanes; D012878:Skin Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D014467:Ultraviolet Therapy / Q000379:methods*
D004273:DNA, Neoplasm; D007211:Indoles; D009942:Organometallic Compounds; D017646:Organosilicon Compounds; D011838:Radiation-Sensitizing Agents; D012821:Silanes; C052736:chloroaluminum tetrasulfophthalocyanine; C082854:silicon phthalocyanine; C052464:bis(tri-n-hexylsiloxy)(2,3-naphthalocyaninato)silicon; D017323:Dihematoporphyrin Ether